Zentrum der Inneren Medizin
4. Wissenschaftliche Veröffentlichungen der Medizinischen Klinik I Journalbeitrag
Originalarbeit
1. Albert, Jörg G (2012) Small bowel imaging in managing Crohn's disease patients.
GASTROENT RES PRACT, 2012: 502198
2. Albert, Jörg G (2012) Interventional balloon-enteroscopy. J INTERV GASTROENTEROL, 2 (1): 42-50
3. Badenhoop K, Kahles H, Penna-Martinez M (2012) Vitamin D, immune tolerance, and prevention of type 1 diabetes. CURR DIABETES REP, 12 (6): 635-42
4. Baker P, Fain P, Kahles H, Yu L, Hutton J, Wenzlau J, Rewers M, Badenhoop K, Eisenbarth G (2012) Genetic determinants of 21-hydroxylase autoantibodies amongst patients of the Type 1 Diabetes Genetics Consortium. J CLIN ENDOCR METAB, 97 (8): E1573-8
5. Bauer AF, Sonzogni S, Meyer L, Zeuzem S, Piiper A, Biondi RM, Neimanis S (2012) Regulation of protein kinase C-related protein kinase 2 (PRK2) by an intermolecular PRK2-PRK2 interaction mediated by Its N-terminal domain. J Biol Chem, 287 (24): 20590-602 6. Bergis D, Friedrich-Rust M, Zeuzem S, Betz C, Sarrazin C, Bojunga J (2012) Treatment of
Amanita phalloides intoxication by fractionated plasma separation and adsorption (Prometheus®). J GASTROINTEST LIVER, 21 (2): 171-6
7. Bezemer G, Van Gool AR, Verheij-Hart E, Hansen BE, Lurie Y, Esteban JI, Lagging M, Negro F, Zeuzem S, Ferrari C, Pawlotsky JM, Neumann AU, Schalm SW, de Knegt RJ, DITTO-HCV Study Group (2012) Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC GASTROENTEROL, 12: 11
8. Biermer M, Schlosser B, Fülöp B, van Bömmel F, Brodzinski A, Heyne R, Keller K, Sarrazin C, Berg T (2012) High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J VIRAL HEPATITIS, 19 (8):
547-53
9. Blumenstein I, Borger D, Loitsch S, Bott C, Tessmer A, Hartmann F, Stein J (2012) A glycerin hydrogel-based wound dressing prevents peristomal infections after percutaneous endoscopic gastrostomy (PEG): a prospective, randomized study. NUTR CLIN PRACT, 27 (3): 422-5
10. Bojunga J, Dauth N, Berner C, Meyer G, Holzer K, Voelkl L, Herrmann E, Schroeter H, Zeuzem S, Friedrich-Rust M (2012) Acoustic radiation force impulse imaging for differentiation of thyroid nodules. PLoS One, 7 (8): e42735
11. Borràs E, Pineda M, Brieger A, Hinrichsen I, Gómez C, Navarro M, Balmaña J, Ramón Y Cajal T, Torres A, Brunet J, Blanco I, Plotz G, Lázaro C, Capellá G (2012) Comprehensive functional assessment of MLH1 variants of unknown significance. HUM MUTAT, 33 (11):
1576-88
12. Brachmann AO, Reimer D, Lorenzen W, Augusto Alonso E, Kopp Y, Piel J, Bode HB (2012) Reciprocal cross talk between fatty acid and antibiotic biosynthesis in a nematode symbiont.
ANGEW CHEM INT EDIT, 51 (48): 12086-9
13. Brieger A, Plotz G, Hinrichsen I, Passmann S, Adam R, Zeuzem S (2012) C-terminal fluorescent labeling impairs functionality of DNA mismatch repair proteins. PLoS One, 7 (2):
e31863
14. Brück P, Pierzchlewska M, Kaluzna-Oleksy M, Ramos Lopez ME, Rummel M, Hoelzer D, Böhme A (2012) Dying of hematologic patients--treatment characteristics in a German University Hospital. SUPPORT CARE CANCER, 20 (11): 2895-902
15. Buerger C, Richter B, Woth K, Salgo R, Malisiewicz B, Diehl S, Hardt K, Boehncke S, Boehncke WH (2012) Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis.. J INVEST DERMATOL, 132 (9): 2206-14
16. Busschots K, Lopez-Garcia LA, Lammi C, Stroba A, Zeuzem S, Piiper A, Alzari PM, Neimanis S, Arencibia JM, Engel M, Schulze JO, Biondi RM (2012) Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. CHEM BIOL, 19 (9): 1152-63
17. Casper M, Plotz G, Juengling B, Zeuzem S, Lammert F, Raedle J (2012) MUTYH hotspot mutations in unselected colonoscopy patients. COLORECTAL DIS, 14 (5): e238-44
18. d'Alquen D, De Boeck K, Bradley J, Vávrová V, Dembski B, Wagner TOF, Pfalz A, Hebestreit H (2012) Quality assessment of expert answers to lay questions about cystic fibrosis from various language zones in Europe: the ECORN-CF project. BMC MED RES METHODOL, 12: 11
19. Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P (2012) Predicted effects of treatment for HCV infection vary among European countries. GASTROENTEROLOGY, 143 (4): 974-85.e14
20. Effraimidis G, Badenhoop K, Tijssen JGP, Wiersinga WM (2012) Vitamin D deficiency is not associated with early stages of thyroid autoimmunity. EUR J ENDOCRINOL, 167 (1): 43-8 21. Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E,
Suppiah V, Booth DR, Stewart GJ, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T (2012) Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. HEPATOLOGY, 55 (6):
1700-10
22. Forestier N, Gaus A, Herrmann E, Sarrazin C, Bojunga J, Poynard T, Albert J, Gerber L, Schneider MD, Dultz G, Zeuzem S, Friedrich-Rust M (2012) Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. J GASTROINTEST LIVER, 21 (4): 367-73
23. Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, Zeuzem S, Bojunga J (2012) Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. EUR J RADIOL, 81 (3):
e325-31
24. Friedrich-Rust M, Romenski O, Meyer G, Dauth N, Holzer K, Grünwald F, Kriener S, Herrmann E, Zeuzem S, Bojunga J (2012) Acoustic Radiation Force Impulse-Imaging for the evaluation of the thyroid gland: a limited patient feasibility study. ULTRASONICS, 52 (1):
69-74
25. Friedrich-Rust M, Nierhoff J, Lupsor M, Sporea I, Fierbinteanu-Braticevici C, Strobel D, Takahashi H, Yoneda M, Suda T, Zeuzem S, Herrmann E (2012) Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J VIRAL HEPATITIS, 19 (2): e212-9
26. Giacometti R, Kronberg F, Biondi RM, Hernández AI, Passeron S (2012) Cross regulation between Candida albicans catalytic and regulatory subunits of protein kinase A. FUNGAL GENET BIOL, 49 (1): 74-85
27. Hamdi N, El-Akel W, El-Serafy M, Esmat G, Sarrazin C, Abdelaziz AI (2012) Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response. INTERVIROLOGY, 55 (3): 210-8 28. Haupenthal J, Bihrer V, Korkusuz H, Kollmar O, Schmithals C, Kriener S, Engels K, Pleli T,
Benz A, Canamero M, Longerich T, Kronenberger B, Richter S, Waidmann O, Vogl TJ, Zeuzem S, Piiper A (2012) Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia, 14 (5): 410-9 29. Hindie V, Lopez-Garcia LA, Biondi RM (2012) Use of a fluorescent ATP analog to probe the
allosteric conformational change in the active site of the protein kinase PDK1. METHODS MOL BIOL, 928: 133-41
30. Hofmann WP, Sarrazin C, Zeuzem S (2012) Current standards in the treatment of chronic hepatitis C. DTSCH ARZTEBL INT, 109 (19): 352-8
31. Hofmann WP, Sarrazin C, Zeuzem S (2012) Correspondence (reply): In Reply. DTSCH ARZTEBL INT, 109 (44): 755-6
32. Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP (2012) Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. HEPATOLOGY, 56 (2): 567-75
33. Kabaçam G, Dalekos GN, Çakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçin K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C (2012) Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. TURK J GASTROENTEROL, 23 (5): 560-8
34. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G (2012) Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One, 7 (4): e34372
35. Korkusuz H, Knau L, Kromen W, Huebner F, Hammerstingl R, Lindemayr S, Bihrer V, Piiper A, Vogl TJ (2012) Gadoxetate acid-enhanced MRI of hepatocellular carcinoma in a
c-myc/TGFα transgenic mouse model including signal intensity and fat content: initial experience.. CANCER IMAGING, 12: 72-8
36. Korkusuz H, Knau LL, Kromen W, Bihrer V, Keese D, Piiper A, Vogl TJ (2012) Different signal intensity at Gd-EOB-DTPA compared with Gd-DTPA-enhanced MRI in hepatocellular carcinoma transgenic mouse model in delayed phase hepatobiliary imaging. J MAGN RESON IMAGING, 35 (6): 1397-402
37. Korkusuz H, Ulbrich K, Bihrer V, Welzel K, Chernikov V, Knobloch T, Petersen S, Huebner F, Ackermann H, Gelperina S, Korkusuz Y, Kromen W, Hammerstingl R, Haupenthal J, Fiehler J, Zeuzem S, Kreuter J, Vogl TJ, Piiper A (2012) Contrast enhancement of the brain by folate-conjugated gadolinium-diethylenetriaminepentaacetic acid-human serum albumin nanoparticles by magnetic resonance imaging. MOL IMAGING, 11 (4): 272-9
38. Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, Sarrazin C, Hoste E, Van Vlierberghe H, Escorsell A, Hafer C, Schreiner O, Galle PR, Mancini E, Caraceni P, Karvellas CJ, Salmhofer H, Knotek M, Ginès P, Kozik-Jaromin J, Rifai K, HELIOS Study Group (2012) Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. GASTROENTEROLOGY, 142 (4): 782-789.e3
39. Kronenberger B, Rudloff I, Bachmann M, Brunner F, Kapper L, Filmann N, Waidmann O, Herrmann E, Pfeilschifter J, Zeuzem S, Piiper A, Muhl H (2012) Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study. BMC MED, 10 (1):
102
40. Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF, Geier A, Gerlach TJ, Heim MH, Malinverni R, Negro F, Regenass S, Badenhoop K, Bojunga J, Sarrazin C, Zeuzem S, Müller T, Berg T, Bochud PY, Moradpour D, Swiss Hepatitis C Cohort Study Group (2012) A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS One, 7 (7): e40159
41. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, Dufour JF, Gerlach TJ, Heim MH, Malinverni R, Müllhaupt B, Negro F, Moradpour D, Bochud PY (2012) Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. HEPATOLOGY, 55 (4): 1038-47
42. Leistner DM, Seeger FH, Fischer A, Röxe T, Klotsche J, Iekushi K, Seeger T, Assmus B, Honold J, Karakas M, Badenhoop K, Frantz S, Dimmeler S, Zeiher AM (2012) Elevated levels of the mediator of catabolic bone remodeling RANKL in the bone marrow environment link chronic heart failure with osteoporosis. CIRC-HEART FAIL, 5 (6): 769-77
43. Liese J, Schreckenbach T, Wahle M, Welker MW, Ulrich F, Bechstein WO, Moench C (2012) [Rare cause of acute liver failure]. CHIRURG, 83 (8): 732-5
44. Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Nájera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, Seiwert SD (2012) Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. ANTIMICROB AGENTS CH, 56 (1): 271-9
45. Lynen Jansen P, Zeuzem S (2012) [In Process Citation]. Z GASTROENTEROL, 50 (8): 959-60
46. Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H, Hep- Net/International Delta Hepatitis Study Group (2012) Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. ANTIVIR THER, 17 (2): 305-12
47. Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, Dalekos GN, Manns MP, Wedemeyer H, Hep-Net/International Delta Hepatitis Study Group (2012) Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. J VIRAL HEPATITIS, 19 (6): 387-95
48. Meyer G, Hackemann A, Reusch J, Badenhoop K (2012) Nocturnal hypoglycemia identified by a continuous glucose monitoring system in patients with primary adrenal insufficiency (Addison's Disease). DIABETES TECHNOL THE, 14 (5): 386-8
49. Meyer SD, Dierynck I, Ghys A, Beumont M, Daems B, Baelen BV, Sullivan JC, Bartels DJ, Kieffer TL, Zeuzem S, Picchio G (2012) Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial.
HEPATOLOGY, 56 (6): 2106-15
50. Moreno C, Berg T, Tanwandee T, Thongsawat S, Van Vlierberghe H, Zeuzem S, Lenz O, Peeters M, Sekar V, De Smedt G (2012) Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J HEPATOL, 56 (6): 1247-53
51. Müllenbach R, Weber SN, Krawczyk M, Zimmer V, Sarrazin C, Lammert F, Grünhage F (2012) A frequent variant in the human bile salt export pump gene ABCB11 is associated with hepatitis C virus infection, but not liver stiffness in a German population. BMC GASTROENTEROL, 12: 63
52. Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros PJ, Rodríguez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G (2012) Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. ANN HEPATOL, 11 (1): 15-31 53. Oksnes M, Bensing S, Hulting AL, Kämpe O, Hackemann A, Meyer G, Badenhoop K,
Betterle C, Parolo A, Giordano R, Falorni A, Papierska L, Jeske W, Kasperlik-Zaluska AA, Chatterjee VKK, Husebye ES, Løvås K (2012) Quality of life in European patients with Addison's disease: validity of the disease-specific questionnaire AddiQoL. J CLIN ENDOCR METAB, 97 (2): 568-76
54. Oertel BG, Vermehren J, Zimmermann M, Huynh TT, Doehring A, Ferreiros N, Senzel S, Schmitz-Rixen T, Erbe M, Geisslinger G, Harder S, Angst MS, Lötsch J (2012) Necessity and risks of arterial blood sampling in healthy volunteer studies. CLIN PHARMACOKINET, 51 (10): 629-38
55. Penna-Martinez M, Ramos-Lopez E, Stern J, Kahles H, Hinsch N, Hansmann ML, Selkinski I, Grünwald F, Vorländer C, Bechstein WO, Zeuzem S, Holzer K, Badenhoop K (2012) Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma. THYROID, 22 (7): 709-16
56. Persson EC, Quraishi SM, Welzel TM, Carreon JD, Gridley G, Graubard BI, McGlynn KA (2012) Risk of liver cancer among US male veterans with cirrhosis, 1969-1996. BRIT J CANCER, 107 (1): 195-200
57. Petersen J, Ratziu V, Buti M, Janssen HLA, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, Lutgehetmann M, Buggisch P (2012) Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J HEPATOL, 56 (3): 520-6
58. Peveling-Oberhag J, Crisman G, Schmidt A, Döring C, Lucioni M, Arcaini L, Rattotti S, Hartmann S, Piiper A, Hofmann WP, Paulli M, Küppers R, Zeuzem S, Hansmann ML (2012) Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection. LEUKEMIA, 26 (7): 1654-62
59. Pianko S, Zeuzem S, Chuang WL, Foster GR, Sarin SK, Flisiak R, Lee CM, Andreone P, Piratvisuth T, Shah S, Sood A, George J, Gould M, Komolmit P, Thongsawat S, Tanwandee T, Rasenack J, Li Y, Pang M, Yin Y, Feutren G, Jacobson IM, B2202 Study Team (2012) Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. J VIRAL HEPATITIS, 19 (9): 623-34
60. Plotz G, Casper M, Raedle J, Hinrichsen I, Heckel V, Brieger A, Trojan J, Zeuzem S (2012) MUTYH gene expression and alternative splicing in controls and polyposis patients. HUM MUTAT, 33 (7): 1067-74
61. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR, SPRINT-2 and RESPOND-2 Investigators (2012) Factors that predict response of patients with hepatitis C virus infection to boceprevir.
GASTROENTEROLOGY, 143 (3): 608-18.e1-5
62. Randriamboavonjy V, Isaak J, Elgheznawy A, Pistrosch F, Frömel T, Yin X, Badenhoop K, Heide H, Mayr M, Fleming I (2012) Calpain inhibition stabilizes the platelet proteome and reactivity in diabetes. BLOOD, 120 (2): 415-23
63. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K, Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T (2012) Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial.. ANN INTERN MED, 157 (2): 94-103
64. Schott E, Ebert MP, Trojan J (2012) Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management. Z GASTROENTEROL, 50 (9):
1018-27
65. Shimakami T, Yamane D, Welsch C, Hensley L, Jangra RK, Lemon SM (2012) Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus. J VIROL, 86 (13): 7372-83
66. Smaczny C, Born T, Wagner TOF (2012) [Emergencies in adult mucoviscidosis patients].
INTERNIST, 53 (5): 575-84
67. Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CAB, Hansen BE, Zeuzem S, Janssen HLA (2012) Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. ANTIVIR THER, 17 (1):
9-17
68. Sonneveld MJ, Rijckborst V, Zeuzem S, Heathcote EJ, Simon K, Senturk H, Pas SD, Hansen BE, Janssen HLA (2012) Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
HEPATOLOGY, 56 (1): 67-75
69. Sonneveld MJ, Rijckborst V, Zwang L, Zeuzem S, Jenny Heathcote E, Simon K, Zoutendijk R, Akarca US, Pas SD, Hansen BE, Janssen HLA (2012) Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants. ANTIVIR RES, 97 ((3)): 312-317
70. Sonneveld MJ, Wong VWS, Woltman AM, Wong GLH, Cakaloglu Y, Zeuzem S, Buster EHCJ, Uitterlinden AG, Hansen BE, Chan HLY, Janssen HLA (2012) Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. GASTROENTEROLOGY, 142 (3): 513-520.e1
71. Sporea I, Bota S, Peck-Radosavljevic M, Sirli R, Tanaka H, Iijima H, Badea R, Lupsor M, Fierbinteanu-Braticevici C, Petrisor A, Saito H, Ebinuma H, Friedrich-Rust M, Sarrazin C, Takahashi H, Ono N, Piscaglia F, Borghi A, D'Onofrio M, Gallotti A, Ferlitsch A, Popescu A, Danila M (2012) Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. EUR J RADIOL, 81 (12):
4112-8
72. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S, Diago M, Arora S, Foster GR, Torbenson M, Benhamou Y, Nelson DR, Sulkowski MS, Zeuzem S, Pulkstenis E, Subramanian GM, McHutchison JG (2012) Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. GUT, 61 (1): 128-34
73. van Bömmel F, Trojan J, Deterding K, Wedemeyer H, Wasmuth HE, Hüppe D, Möller B, Bock FJ, Feucht HH, Berg T (2012) Evolution of adefovir-resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy. ANTIVIR THER, 17 (6): 1049-58
74. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HLA (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA-J AM MED ASSOC, 308 (24): 2584-93
75. Vermehren J, Lötsch J, Susser S, Wicker S, Berger A, Zeuzem S, Sarrazin C, Doehring A (2012) A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers. PLoS One, 7 (3): e32605
76. Vermehren J, Polta A, Zimmermann O, Herrmann E, Poynard T, Hofmann WP, Bojunga J, Sarrazin C, Zeuzem S, Friedrich-Rust M (2012) Comparison of acoustic radiation force
impulse imaging with transient elastography for the detection of complications in patients with cirrhosis. LIVER INT, 32 (5): 852-8
77. Vermehren J, Schlosser B, Domke D, Elanjimattom S, Müller C, Hintereder G, Hensel-Wiegel K, Tauber R, Berger A, Haas N, Walcher F, Möckel M, Lehmann R, Zeuzem S, Sarrazin C, Berg T (2012) High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28,809 patients. PLoS One, 7 (7): e41206
78. Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C (2012) Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J CLIN VIROL, 55 (1): 17-22
79. Vermehren J, Vermehren A, Mueller A, Carlebach A, Lutz T, Gute P, Knecht G, Sarrazin C, Friedrich-Rust M, Forestier N, Poynard T, Zeuzem S, Herrmann E, Hofmann WP (2012) Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. BMC GASTROENTEROL, 12: 27
80. Vermehren J, Susser S, Lange CM, Forestier N, Karey U, Hughes E, Ralston R, Tong X, Zeuzem S, Sarrazin C (2012) Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b. J VIRAL HEPATITIS, 19 (2): 120-7
81. Vogl TJ, Naguib NNN, Nour-Eldin NEA, Bechstein WO, Zeuzem S, Trojan J, Gruber-Rouh T (2012) Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success. INT J CANCER, 131 (3): 733-40
82. von Hahn T, Schiene-Fischer C, Van ND, Pfaender S, Karavul B, Steinmann E, Potthoff A, Strassburg C, Hamdi N, Abdelaziz AI, Sarrazin C, Müller T, Berg T, Trépo E, Wedemeyer H, Manns MP, Pietschmann T, Ciesek S (2012) Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. GASTROENTEROLOGY, 143 (2): 439-47.e1
83. Waidmann O, Bihrer V, Pleli T, Farnik H, Berger A, Zeuzem S, Kronenberger B, Piiper A (2012) Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J VIRAL HEPATITIS, 19 (2): e58-65
84. Waidmann O, Bihrer V, Kronenberger B, Zeuzem S, Piiper A, Forestier N (2012) Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection. DIGEST LIVER DIS, 44 (5): 438-41
85. Waidmann O, Köberle V, Brunner F, Zeuzem S, Piiper A, Kronenberger B (2012) Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One, 7 (9): e45652 86. Welker MW, Reichert D, Susser S, Sarrazin C, Martinez Y, Herrmann E, Zeuzem S, Piiper A,
Kronenberger B (2012) Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity. PLoS One, 7 (2): e30796
87. Welker MW, Susser S, Welsch C, Perner D, Füller C, Kronenberger B, Herrmann E, Zeuzem S, Sarrazin C (2012) Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site-directed mutagenesis of an NS4B aminoterminal basic leucine zipper. J VIRAL HEPATITIS, 19 (11): 775-83
88. Welsch C, Schweizer S, Shimakami T, Domingues FS, Kim S, Lemon SM, Antes I (2012) Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease.
ANTIMICROB AGENTS CH, 56 (4): 1907-15
89. Welsch C, Shimakami T, Hartmann C, Yang Y, Domingues FS, Lengauer T, Zeuzem S, Lemon SM (2012) Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
GASTROENTEROLOGY, 142 (3): 654-63
90. Welsch C, Zeuzem S (2012) Will interferon-free regimens prevail?
GASTROENTEROLOGY, 142 (6): 1351-5
91. Welsch C, Zeuzem S (2012) Clinical relevance of HCV antiviral drug resistance. CURR OPIN VIROL, 2 (5): 651-5
92. Wicker S, Rabenau HF, Haberl AE, Bühren A, Bechstein WO, Sarrazin CM (2012) [Blood-borne infections and the pregnant health care worker. Risks and preventive measures].
CHIRURG, 83 (2): 136-42
93. Wilhelm A, Lopez-Garcia LA, Busschots K, Fröhner W, Maurer F, Boettcher S, Zhang H, Schulze JO, Biondi RM, Engel M (2012) 2-(3-Oxo-1,3-diphenylpropyl)malonic acids as potent allosteric ligands of the PIF pocket of phosphoinositide-dependent kinase-1:
development and prodrug concept. J MED CHEM, 55 (22): 9817-30
94. Zeuzem S, Rodríguez-Torres M, Rajender Reddy K, Marcellin P, Diago M, Craxi A, Pockros P, Rizzetto M, Bernstein D, Shiffman ML, Lin A, Tatsch F, Hadziyannis S (2012) Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin. J VIRAL HEPATITIS, 19 (11): 766-74
95. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR (2012) The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. HEPATOLOGY, 55 (3): 749-58
Review
1. Albert JG, Helmbold P (2012) [Diagnosis of intestinal metastases from malignant melanoma].
DEUT MED WOCHENSCHR, 137 (9): 431-6
2. Boehncke WH, Boehncke S, Buerger C (2012) [Beyond immunopathogenesis. Insulin resistance and "epidermal dysfunction"]. HAUTARZT, 63 (3): 178-83
3. Boehncke WH, Boehncke S (2012) Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. CURR RHEUMATOL REP, 14 (4): 343-8
4. Dignass A, Faiss S, Galle P, Layer P, Lerch M, Malfertheiner P, Wehrmann T, Zeuzem S (2012) [Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dosage evaluation)]. Z GASTROENTEROL, 50 (1): 20-1
5. Farnik H, Zeuzem S (2012) New antiviral therapies in the management of HCV infection.
ANTIVIR THER, 17 (5): 771-83
6. Forestier N, Zeuzem S (2012) Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders. LIVER INT, 32 (Suppl 1): 44-50
7. Forestier N, Zeuzem S (2012) Telaprevir for the treatment of hepatitis C. EXPERT OPIN PHARMACO, 13 (4): 593-606
8. Halfon P, Sarrazin C (2012) Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? LIVER INT, 32 (Suppl 1): 79-87
9. Kronenberger B, Zeuzem S (2012) New developments in HCV therapy. J VIRAL HEPATITIS, 19 (Suppl 1): 48-51
10. Rödel C, Trojan J, Bechstein WO, Woeste G (2012) Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated? DIGEST DIS, 30 (Suppl 2): 102-8
11. Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S (2012) [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z GASTROENTEROL, 50 (1): 57-72
12. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM (2012) Antiviral strategies in hepatitis C virus infection. J HEPATOL, 56 (Suppl 1): S88-100
13. Vermehren J, Sarrazin C (2012) The role of resistance in HCV treatment. BEST PRACT RES CL GA, 26 (4): 487-503
14. Vogl TJ, Zangos S, Eichler K, Gruber-Rouh T, Hammerstingl RM, Trojan J, Weisser P (2012) [Radiological diagnosis and intervention of cholangiocarcinomas (CC)]. ROFO-FORTSCHR RONTG, 184 (10): 883-92
15. Welsch C, Jesudian A, Zeuzem S, Jacobson I (2012) New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. GUT, 61 (Suppl 1): i36-46
Weiter- und Fortbildung
1. Grammatikos G, Vermehren J, Zeuzem S (2012) [Chronic hepatitis C: improved cure rates with new approved medications]. MMW FORTSCHR MED, O 154 (Suppl 2): 65-9; quiz 70
Editorial
1. Welzel TM, Zeuzem S (2012) NS5A inhibitors to treat hepatitis C virus infection. LANCET INFECT DIS, 12 (9): 648-9
Fallbericht
1. Burkhard T, Peveling-Oberhag J, Vogl TJ (2012) [Painless jaundice: a clear case?].
RADIOLOGE, 52 (8): 756-60
2. Koch C, Paetzold S, Trojan J (2012) Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma. GASTROENTEROLOGY, 143 (2): 298, 504, 505
Buchbeitrag
1. Born T, Lais C, Smaczny C, Wagner TOF (2012) Bestimmung des Zeitpunkts der Listung zur Transplantation. In: Tim O. Hirche; Thomas O. F. Wagner (Hg.) Update Mukoviszidose:
Lungentransplantation.. GEORG THIEME VERLAG, Stuttgart, 18-20
2. D’Alquen D, Hirche TO, Pfalz A, Wagner TOF (2012) ECORN-CF und Transplantation:
Fragen/Antworten aus dem europäischen Netzwerk. In: Tim O. Hirche; Thomas O. F. Wagner (Hg.) Update Mukoviszidose: Lungtentransplantation. GEORG THIEME VERLAG, Stuttgart, 9-14
3. Gleiber W (2012) Transplantationsvorbereitung/präoperative Untersuchungen. In: Tim O.
Hirche; Thomas O. F. Wagner (Hg.) Update Mukoviszidose: Lungtentransplantation..
GEORG THIEME VERLAG, Stuttgart, 27-28 4.
Dissertation
1. Hackemann A (2012) Pathophysiologie, Verlauf und Einflussfaktoren auf die Lebensqualität von Patienten mit autoimmunbedingter Nebennierenrindeninsuffizuienz (Morbus Addison).
2. König AB (2012) Frankfurter Gestationsdiabetes Qutcome-Studie.
3. Robbers IE (2012) Genvarianten der Immunregulation bei den Autoimmunopathien Hashimoto-Thyreoditis, Morbus Basedow und Morbus Addison.
Habilitation
1. Brieger A (2012) Intrazellulärer Transport des humanen DAN-Mismatch-Reparaturproteins MLH1 und Untersuchung seiner Interaktion mit Reparatur-unabhängigen Proteinen.
2. Maria Elizabeth RL (2012) Funktionelle Auswirkung von Genvarianten im Vitamin D-System auf die Entstehung des Typ 1 Diabetes.
3. Welker MW (2012) Bedeutung des Strukturproteins E2 und des Nichtstrukturproteins 4B des Hepatitis -C- Virus für den viralen Replikationszyklus und das Therapieansprechen bei Interferon-ALFA-basierter antiviraler Therapie.